Eveleen J Darby
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eveleen J Darby has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Rachelle S. Doody
Baylor College of Medicine, Houston, TX, USA
1 shared publication - Susan D. Rountree
Alzheimer's Disease and Memory Disorders Center, Baylor College of Medicine, 6501 Fannin Street, NB302, Houston, TX 77030, USA
1 shared publication - Valory N. Pavlik
Baylor College of Medicine, Houston, TX, USA
1 shared publication - Wenyaw Chan
Department of Biostatistics and Data Science, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
1 shared publication
Latest Publications
- Open Access
- 15 May 2012
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 4 (3) , 16
Factors that influence survival in a probable Alzheimer disease cohort
Introduction: This longitudinal study examined multiple factors that influence survival in a cohort of Alzheimer patients followed over two decades. Methods: Time to death after symptom onset was determined in 641 probable AD patients who were evaluated annually until death or loss to follow-up, and information was entered into a longitudinal database. Date of death was available for everyone including those eventually lost. Baseline variables included age, sex, race, disease severity, a calculated index of rate of initial cognitive decline from symptom onset to cohort entry (pre-progression rate or PPR), years of education, and medical comorbidities (diabetes, hypertension, hyperlipidemia, coronary disease, cerebrovascular disease). Multivariable Cox proportional hazard regression analysis was used to analyze the baseline and/or time dependent association in Mini-mental Status Exam (MMSE) severity, Physical Self Maintenance Scale (PSMS), Persistency Index (PI) of exposure to antipsychotic and antidementia drugs, and psychotic symptoms (hallucinations, delusions) with mortality. Results: Baseline covariates significantly associated with increased survival were younger age (p = .0016), female sex (p = .0001), and a slower PPR (p < .0001). Overall disease severity at baseline, medical comorbidities, and education did not influence time to death. Time-dependent changes in antipsychotic drug use, development of psychotic symptoms, antidementia drug use, and observed MMSE change were not predictive. In the final model the only time-dependent covariate that significantly decreased survival was worsening of functional ability on the PSMS (hazard ratio = 1.10; CI: 1.07-1.11). Conclusions: In this large AD cohort survival is influenced by age, sex, and the development of functional disability during follow-up. The most important predictor of mortality was a faster rate of cognitive decline at the initial patient visit (PPR). The currently available antidementia drugs do not prolong survival in Alzheimer patients.
- 15 May 2012
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 4 (3) , 16
Open AccessFactors that influence survival in a probable Alzheimer disease cohort
Introduction: This longitudinal study examined multiple factors that influence survival in a cohort of Alzheimer patients followed over two decades. Methods: Time to death after symptom onset was determined in 641 probable AD patients who were evaluated annually until death or loss to follow-up, and information was entered into a longitudinal database. Date of death was available for everyone including those eventually lost. Baseline variables included age, sex, race, disease severity, a calculated index of rate of initial cognitive decline from symptom onset to cohort entry (pre-progression rate or PPR), years of education, and medical comorbidities (diabetes, hypertension, hyperlipidemia, coronary disease, cerebrovascular disease). Multivariable Cox proportional hazard regression analysis was used to analyze the baseline and/or time dependent association in Mini-mental Status Exam (MMSE) severity, Physical Self Maintenance Scale (PSMS), Persistency Index (PI) of exposure to antipsychotic and antidementia drugs, and psychotic symptoms (hallucinations, delusions) with mortality. Results: Baseline covariates significantly associated with increased survival were younger age (p = .0016), female sex (p = .0001), and a slower PPR (p < .0001). Overall disease severity at baseline, medical comorbidities, and education did not influence time to death. Time-dependent changes in antipsychotic drug use, development of psychotic symptoms, antidementia drug use, and observed MMSE change were not predictive. In the final model the only time-dependent covariate that significantly decreased survival was worsening of functional ability on the PSMS (hazard ratio = 1.10; CI: 1.07-1.11). Conclusions: In this large AD cohort survival is influenced by age, sex, and the development of functional disability during follow-up. The most important predictor of mortality was a faster rate of cognitive decline at the initial patient visit (PPR). The currently available antidementia drugs do not prolong survival in Alzheimer patients.